Subutex is buprenorphine without naloxone — clinically equivalent to Suboxone for the buprenorphine effect, and specifically indicated during pregnancy or when naloxone is contraindicated.
Kentucky Medicaid plans typically cover buprenorphine monoproduct (Subutex / generic buprenorphine), with most plans requiring documentation of the clinical indication. Pregnancy-related authorizations are typically expedited.
Subutex is the preferred buprenorphine formulation during pregnancy. Naloxone (the second ingredient in Suboxone) is contraindicated in pregnancy because of potential fetal harm, so prescribers move pregnant patients to Subutex while maintaining the same induction and maintenance approach.
A small subset of patients have documented sensitivity or adverse reaction to naloxone. For these patients, Subutex provides the same therapeutic buprenorphine without the second-line ingredient that triggered the reaction.
In some clinical contexts a prescriber may choose Subutex over Suboxone — for example, when initiating MAT in a controlled setting where misuse risk is already addressed by clinical observation.
Subutex is buprenorphine alone. Suboxone is buprenorphine plus naloxone — an opioid antagonist added to deter misuse via injection. For oral/sublingual use as intended, the two are clinically equivalent. Suboxone is the more common prescription because the naloxone serves as an abuse-deterrent layer.
Naloxone in Suboxone is contraindicated in pregnancy because of potential fetal harm. Subutex removes the naloxone while keeping the therapeutic buprenorphine, making it the standard buprenorphine formulation for pregnant patients with opioid use disorder. Treatment with buprenorphine during pregnancy is the clinical standard — untreated OUD carries far higher fetal risk than the medication.
Kentucky Medicaid plans typically cover Subutex, with most plans requiring documentation of the clinical indication (typically pregnancy) for prior authorization. Pregnancy-related authorizations are usually expedited.
Yes, when clinically appropriate. The switch is straightforward because the therapeutic component (buprenorphine) is identical. Most patients notice no clinical difference. Your prescriber walks through the decision and timing with you.
The brand-name Subutex was discontinued in the U.S., but generic buprenorphine monoproduct (the same medication) remains widely available and prescribed. Pharmacies and prescribers typically refer to it as 'buprenorphine' or 'buprenorphine monoproduct.'
24/7 admissions. Insurance verification in minutes. Most KY Medicaid plans accepted. No judgment, no pressure, no obligation.